Related references
Note: Only part of the references are listed.Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2020)
Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
Ran Ran et al.
ONCOTARGETS AND THERAPY (2020)
ZiYinHuaTan Recipe Inhibits Cell Proliferation and Promotes Apoptosis in Gastric Cancer by Suppressing PI3K/AKT Pathway
Jiahui Yu et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF-κB Pathways
Ran Duan et al.
BIOMED RESEARCH INTERNATIONAL (2020)
The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR plus Breast Cancer Therapy: A Systematic Review and Meta-Analysis
Mingming Wang et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
Anja Welt et al.
CANCER MEDICINE (2020)
Topical application of honey in the management of chemo/radiotherapy-induced oral mucositis: A systematic review and network meta-analysis
Chao Yang et al.
INTERNATIONAL JOURNAL OF NURSING STUDIES (2019)
Cancer statistics for African Americans, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Benefits versus risk profile of buparlisib for the treatment of breast cancer
Anne Patsouris et al.
EXPERT OPINION ON DRUG SAFETY (2019)
TNeoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Cristina Saura et al.
LANCET ONCOLOGY (2019)
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2-Metastatic Breast Cancer: Biological Mechanisms and New Treatments
Daniele Presti et al.
CANCERS (2019)
Efficacy of PI3K inhibitors in advanced breast cancer
B. Verret et al.
ANNALS OF ONCOLOGY (2019)
Superselective arterial embolization with drug-loaded microspheres for the treatment of unresectable breast cancer
Zhiheng Wang et al.
GLAND SURGERY (2019)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing et al.
BREAST CANCER RESEARCH (2019)
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
Sarika Jain et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis
Romina Brignardello-Petersen et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2018)
Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis
Fan Feng et al.
PHARMACOLOGICAL RESEARCH (2018)
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer
Sasha M. Pejerrey et al.
HORMONES & CANCER (2018)
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Mario Campone et al.
EUROPEAN JOURNAL OF CANCER (2018)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)
M. Martin et al.
ANNALS OF ONCOLOGY (2017)
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Sibylle Loibl et al.
EUROPEAN JOURNAL OF CANCER (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer
Angela DeMichele et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
P. Vuylsteke et al.
ANNALS OF ONCOLOGY (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Share Paper
